PMID- 20698208
OWN - NLM
STAT- MEDLINE
DCOM- 20100907
LR  - 20181201
IS  - 0172-6390 (Print)
IS  - 0172-6390 (Linking)
VI  - 57
IP  - 99-100
DP  - 2010 May-Jun
TI  - Prognostic effect of human leukocyte antigen class I and II alleles on chronic 
      hepatitis C patients treated by pegylated interferon-alfa plus ribavirin in 
      Taiwan.
PG  - 456-61
AB  - BACKGROUND/AIMS: To investigate the influence of human leukocyte antigen (HLA) 
      class I and II alleles on the response in chronic hepatitis C (CHC) patients 
      receiving combination therapy with pegylated interferon-alfa and ribavirin. 
      METHODOLOGY: One hundred and six CHC patients who accomplished combination 
      treatment were enrolled. Sixty-seven patients achieved sustained virologic 
      response (SVR). HLA-A, -B, -C, -DR, and -DQ loci were determined by 
      sequence-based genotyping. The effects of virologic variables and HLA alleles on 
      SVR were evaluated by logistic regressions. RESULTS: Univariate analyses showed 
      that SVR was significantly associated with low pre-treatment HCV RNA levels, HCV 
      genotype non-1, high pre-treatment ALT levels, a significant decline of ALT 
      levels from baseline to week 4, and the low body mass index. Among HLA class I 
      and II alleles, the occurrence of SVR was significantly associated with lack of 
      HLA-B60 and existence of HLA-A33 in univariate analyses (OR, 0.33; 95% CI, 
      0.14-0.77; p = 0.01; OR, 2.16; 95% CI, 0.86-5.45; p = 0.30 with a trend, 
      respectively). Multivariate analyses revealed that HLA-A33 significantly favored 
      SVR after adjusted for potential confounders (OR, 7.86; 95% CI, 1.43-43.30; p 
      value after Holm's procedure = 0.03). CONCLUSIONS: HLA-A33 is associated with the 
      achievement of SVR in Taiwanese CHC patients receiving combination therapy with 
      pegylated interferon-alfa plus ribavirin.
FAU - Tseng, Kuo-Chih
AU  - Tseng KC
AD  - Department of Internal Medicine, Buddhist Dalin Tzu Chi General Hospital, 
      Chia-Yi, Taiwan.
FAU - Chang, Chin-Kuo
AU  - Chang CK
FAU - Chou, An-Liang
AU  - Chou AL
FAU - Hsieh, Yu-Hsi
AU  - Hsieh YH
FAU - Tseng, Chang-An
AU  - Tseng CA
FAU - Lai, Ning-Sheng
AU  - Lai NS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Hepatogastroenterology
JT  - Hepato-gastroenterology
JID - 8007849
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (RNA, Viral)
RN  - 0 (Recombinant Proteins)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 49717AWG6K (Ribavirin)
RN  - G8RGG88B68 (peginterferon alfa-2b)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Alleles
MH  - Drug Therapy, Combination
MH  - Female
MH  - *Genes, MHC Class I
MH  - *Genes, MHC Class II
MH  - HLA-DR Antigens/genetics
MH  - Hepatitis C, Chronic/*drug therapy/immunology/virology
MH  - Humans
MH  - Interferon alpha-2
MH  - Interferon-alpha/*administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Polyethylene Glycols/*administration & dosage
MH  - Prognosis
MH  - RNA, Viral/blood
MH  - Recombinant Proteins
MH  - Ribavirin/*administration & dosage
EDAT- 2010/08/12 06:00
MHDA- 2010/09/08 06:00
CRDT- 2010/08/12 06:00
PHST- 2010/08/12 06:00 [entrez]
PHST- 2010/08/12 06:00 [pubmed]
PHST- 2010/09/08 06:00 [medline]
PST - ppublish
SO  - Hepatogastroenterology. 2010 May-Jun;57(99-100):456-61.